REDX.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 13:27):

Stats
Today's Volume	732 013
Average Volume	864 486
Market Cap	50.65M
EPS	£0 ( 2023-12-14 )
Next earnings date	( £0 ) 2024-05-06
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.200
ATR14	£0.340 (2.94%)

Volume Correlation

Long: 0.05 (neutral)

Short: 0.43 (neutral)

Signal:(44.319) Neutral

Redx Pharma PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Redx Pharma PLC Correlation - Currency/Commodity

0.29
( neutral )

0.22
( neutral )

0.26
( neutral )

0.16
( neutral )

-0.32
( neutral )

-0.03
( neutral )

Redx Pharma PLC Financials

Annual	2023
Revenue:	£4.20M
Gross Profit:	£3.24M (77.15 %)
EPS:	£-0.0990

Q4	2023
Revenue:	£1.89M
Gross Profit:	£1.43M (75.46 %)
EPS:	£-0.0370

Q2	2023
Revenue:	£2.31M
Gross Profit:	£2.31M (100.00 %)
EPS:	£-0.0620

Q4	2022
Revenue:	£10.34M
Gross Profit:	£10.34M (100.00 %)
EPS:	£-0.0257

Financial Reports:

No articles found.

Redx Pharma PLC

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.